Tumour-infiltrating lymphocyte scores effectively stratify outcomes over and above p16 post chemo-radiotherapy in anal cancer.
Tumour-infiltrating lymphocyte scores effectively stratify outcomes over and above p16 post chemo-radiotherapy in anal cancer.
复制标题
DOI：
10.1038/bjc.2015.448
复制
发表时间：
2016-01-19
影响因子：
8.8
通讯作者：
Thomas GJ
中科院分区：
文献类型：
--
作者：
Gilbert DC;Serup-Hansen E;Linnemann D;Høgdall E;Bailey C;Summers J;Havsteen H;Thomas GJ
大多数（90%）肛门癌是由人乳头瘤病毒（HPV）驱动的，使用p16免疫化学鉴定。与HPV−患者相比，HPV+患者的生存率通常有所提高，尽管复发率约为25%，但需要对该组进行进一步分层。使用两个队列的肛门癌，以前的特点为p16，我们评估了肿瘤浸润淋巴细胞（TILs）的预后价值。肿瘤浸润淋巴细胞评分用于对p16+病例进行分层，其中不存在/低水平TIL的肿瘤的无复发率为63%，而高水平TIL的无复发率为92%（对数秩P=0.006）。TIL的评估增加了p16状态在化疗-放疗后肛门癌的预后，并提供了免疫应答的临床重要性的证据。
The majority (90%) of anal cancers are human papillomavirus (HPV)-driven, identified using immunochemistry for p16. Compared with HPV− patients, those with HPV+ disease generally show improved survival, although relapse rates around 25% indicate a need for further stratification of this group. Using two cohorts of anal cancer, previously characterised for p16, we assessed the prognostic value of tumour-infiltrating lymphocytes (TILs). Tumour-infiltrating lymphocyte scores were used to stratify p16+ cases, where tumours with absent/low levels of TIL had a relapse-free rate of 63%, as opposed to 92% with high levels of TIL (log rank P=0.006). Assessment of TIL adds to p16 status in the prognosis of anal cancer following chemo-radiotherapy and provides evidence of the clinical importance of the immune response.